title: Alteration of interferon-α/β receptors in chronic hepatitis B patients.
abstract: BACKGROUND
  The present study determined type I interferon (IFN) receptor (interferon-α/β receptor (IFNAR)) and its predicable role in interferon-α2b treatment in chronic hepatitis B (CHB) patients.
  
  
  METHODS
  Expression of IFN-α/βR-1 and IFN-α/βR-2 in peripheral blood mononuclear cells and in liver tissue was measured by flow cytometry, immunofluorescence, immunohistochemistry and RT-PCR.
  
  
  RESULTS
  IFN-α/βR-1 and IFN-α/βR-2 in monocytes and lymphocytes increased in CHB patients. Expression of IFNAR-1 and IFNAR-2 in liver had positive correlation with HBV-DNA in liver tissue. Expression of IFN-α/βR in lymphocytes and monocytes increased in the first month, but then decreased during the subsequent interferon-α2b treatment, patients who had higher levels of IFN-α/βR-2 in monocytes prior to therapy showed better viral response than those with lower levels.
  
  
  CONCLUSIONS
  Expression of IFN-α/βR-2 in monocytes can be used as a predictable parameter to evaluate the effect of IFN-α treatment in CHB patients.
authors: Department of Hepatology, Qilu Hospital, Shandong University, 107 Wenhua Xi Road, 250012, Jinan, People's Republic of China.
authors: Fanli
authors: F
authors: Meng
authors: Jiefei
authors: J
authors: Wang
authors: Jian
authors: J
authors: Ge
authors: Xiaopeng
authors: X
authors: Fan
authors: Bing
authors: B
authors: Wang
authors: Liyan
authors: L
authors: Han
authors: Tatiana
authors: T
authors: Kisseleva
authors: YongHan
authors: Y
authors: Paik
authors: David A
authors: DA
authors: Brenner
authors: Kai
authors: K
authors: Wang
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D004279:DNA, Viral / Q000097:blood* / Q000276:immunology; D005260:Female; D005434:Flow Cytometry; D005455:Fluorescent Antibody Technique; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006513:Hepatitis B e Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000187:drug effects* / Q000276:immunology / Q000502:physiology; D019694:Hepatitis B, Chronic / Q000097:blood / Q000188:drug therapy / Q000276:immunology / Q000473:pathology / Q000821:virology; D006801:Humans; D007150:Immunohistochemistry; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000627:therapeutic use; D007963:Leukocytes, Mononuclear / Q000166:cytology / Q000187:drug effects* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D053633:Receptor, Interferon alpha-beta / Q000097:blood / Q000235:genetics / Q000276:immunology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D019562:Viral Load / Q000187:drug effects
chemical_list: D004279:DNA, Viral; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D016898:Interferon-alpha; D053633:Receptor, Interferon alpha-beta